Endocrinology Search
Endocrinology Endocrinology
hypomagnesemia%20-and-%20hypermagnesemia
HYPOMAGNESEMIA & HYPERMAGNESEMIA
Hypomagnesemia is having a serum magnesium concentration of <1.3 mEq/L.
Patients with mild hypomagnesemia is asymptomatic and have usually a serum Mg >0.5 mmol/L. While those with moderate-severe hypomagnesemia, the patient is symptomatic and have serum Mg <5 mmol/L.
Hypermagnesemia signs and symptoms usually do not appear unless Mg >2 mmol/L (5 mg/dL). It rarely occurs and usually iatrogenic.
  1. Agus ZS. Hypomagnesemia. J Am Soc Nephrol. 1999 Jul;10(7):1616-1622. PMID: 10405219
  2. Dacey MJ. Hypomagnesemic disorders. Crit Care Clin. 2001 Jan;17(1):155-173. PMID: 11219227
  3. Weisinger JR, Bellorin-Font E. Electrolyte quintet: magnesium and phosphorus. Lancet. 1998 Aug;352(9125):391-396. PMID: 9717944
  4. Diseases of the parathyroid gland and other hyper- and hypocalcemic disorders. Harrison's Online: McGraw-Hill Companies; 2003.
  5. Introduction to bone and mineral metabolism. Harrison's Online: McGraw-Hill Companies; 2003.
  6. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  7. Vanden Hoek TL, Morrison LJ, Shuster M, et al. Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2010 Nov;122(Suppl 18):S829-S861. doi: 10.1161/CIRCULATIONAHA.110.971069. PMID: 20956228
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Empagliflozin protects against CV risk factors in type 2 diabetes
16 May 2019
Empagliflozin treatment in patients with type 2 diabetes mellitus exerts beneficial effects on cardiovascular (CV) risk factors, including blood pressure and uric acid, according to a systematic review and meta-analysis.
Metformin protects over 15 years: Time for diabetes prevention indication?
Pearl Toh, 17 May 2019
Metformin continues to protect high-risk individuals from developing type 2 diabetes (T2D) over 15 years, especially among those with higher glycaemic status at baseline and women reporting a history of gestational diabetes mellitus (GDM), according to long-term results from DPP/DPPOS*.
Obesity may constrain physical function, activities among older adults
16 May 2019
Due to the increasing global prevalence of obesity, older adults may live more years of their remaining life with limited physical function and activities in daily living (ADLs), according to a study, adding that older adults, their families and healthcare systems should be aware of this problem.
OAGB vs RYGB: No difference in weight loss, metabolic effects
Jairia Dela Cruz, 6 days ago
One anastomosis gastric bypass is as effective as the standard Roux-en-Y procedure in terms of weight loss and metabolic improvements 24 months after the surgery, according to the results of the open-label YOMEGA trial.